FGK Clinical Research Signs Five-Year Agreement with OmniComm Systems for Multiple eClinical Products

    NEXT STORY
    Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/Trabedersen
    PREV STORY
    Fortress Biotech to Participate in December 2019 Investor Conferences
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Global IV and Oral Iron Drugs Markets 2019-2024 – Investigational Iron Drugs and Expected Approvals in Newer Markets

    author_avatar
    NASDAQ Market News

    ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities

    BOSTON, Aug. 09, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced financial ...

    author_avatar
    NASDAQ Market News

    Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

    – FCX-007 well-tolerated through 12 weeks post-administration with encouraging safety and positive early trends ...

    author_avatar
    NASDAQ Market News